February 2025
Published: 10 Feb 2025
Author: Precedence Research
The Extended Access Program (EAP) for LP-310, an oral rinse formulation for the treatment of oral lichen planus (OLP), has been approved by the FDA for Lipella Pharmaceuticals Inc. This is indeed a meaningful step toward alleviating the suffering of patients with this chronic inflammatory condition. Oral lichen planus is a painful chronic inflammatory condition affecting the mucous membranes inside the mouth, with approximately 6 million Americans affected. Currently, no FDA-approved treatments exist for this condition; therefore, targeted therapy development such as LP-310 is a breakthrough.
LP-310 is a localized therapy designed to give targeted relief to patients suffering from Oral Lung Pain (OLP), while not sacrificing systemic exposure. Unlike traditional systemic treatments, LP-310 is an oral rinse with the active agent directly targeting inflamed areas with no significant absorption into the bloodstream-evidently lessening potential side effects from long-term steroid use and other systemic therapies. Through Expanded Access Programs (EAP), promising therapies that have not yet received FDA approval may be offered to patients with serious or life-threatening conditions outside clinical trials. The approval of LP-310 for EAP allows patients with OLP who are excluded from clinical trials to gain access to the drug with FDA oversight. Mustering excitement over FDA approval, Dr. Michael Chancellor, co-founder and Chief Medical Officer of Lipella Pharmaceuticals iterated that this was a truly monumental milestone within their plan to address the treatment of oral lichen planus concerning a huge unmet need.
LP-310 is a well-known immunosuppressive agent, being an oral rinse formulation aimed at the inflammation and immune response in patients with OLP. A Phase 2a multicenter dose-ranging clinical trial assesses LP-310 safety, tolerability, and efficacy in adult patients with symptomatic OLP. The study with three tacrolimus doses is being conducted in seven active sites across the United States. Findings from this trial will expedite LP-310's journey through the regulatory pathway toward approval as a standard treatment for OLP. The FDA's indication of EAP for LP-310 further underscores the potential for this drug to become an encouraging novel therapeutic option for OLP patients and intensifies the need for active clinical research and development. EAP offers optimism to patients crippled by severe symptoms and may further support decisions for regulatory approval in the largesse. Thus, combinations of higher means to deliver tacrolimus orally locally utilizing advanced delivery systems circumvent the first-pass effect and the rapid systemic excretion of tacrolimus.
LP-310 is a drug that is set to potentially revolutionize the paradigm of treatment for oral lichen planus. Lipella Pharmaceuticals is committed to the clinical development of this drug and trying to obtain FDA approval for marketing. The ongoing Phase 2a trial and regulatory milestones indicate a good future for Lipella Pharmaceuticals and those millions of people afflicted by oral lichen planus. That being said, due to certain forward-looking statements in this release regarding expectations of clinical development, regulatory approval, and commercialization of LP-310, the company wishes to express some caution.
February 2025
February 2025
February 2025
February 2025